NYSE · AVNS
Avanos Medical, Inc.
$24.99+$0.01 (+0.04%)
Avanos Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
Loading market information…
NASDAQ · LAB · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Standard BioTools Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.95% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Standard BioTools Inc.’s next earnings report is currently expected on Nov 3, 2026, with estimated earnings per share of -$0.02. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Standard BioTools Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | -$0.040.0% vs estimate | $40.80M+1.73% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -$0.05+28.57% vs estimate | $46.72M+8.56% vs estimate |
|---|
| Q3 2024 | Oct 30, 2024 | -$0.05+37.5% vs estimate | $44.97M+9.68% vs estimate |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$24.99+$0.01 (+0.04%)
Avanos Medical, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$27.82+$0.60 (+2.2%)
CeriBell, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.31% below the high.
$14.87+$0.22 (+1.5%)
Bioventus Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.44% below the high.
$15.45-$0.11 (-0.71%)
Cullinan Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.38% below the high.
$31.52+$0.72 (+2.34%)
OrthoPediatrics Corp.’s quoted price sits in the upper half of its reported 52-week range, 3.37% below the high.
$6.30+$0.16 (+2.61%)
Cytek Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.47% below the high.
$18.44-$0.01 (-0.05%)
Varex Imaging Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.02% below the high.
$5.06+$0.23 (+4.76%)
Treace Medical Concepts, Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.91% below the high.
